ArticleNature communications2023

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.

Teresa Maria Rosaria Noviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.